Three ways to end up on both drugs
In real life, very few people are started on an SGLT2 inhibitor and a GLP-1 receptor agonist on the same day. The usual path is stepwise. You start one, your numbers improve but not enough, and a few months later the second one is added.
That gives three routes to the same destination:
- Simultaneous: both drugs started together, neither used before.
- GLP-1 first: already on a GLP-1 drug, SGLT2 inhibitor added.
- SGLT2 first: already on an SGLT2 inhibitor, GLP-1 drug added.
The authors ran a subgroup analysis to see whether the route changed the result. This is the kind of question that rarely gets asked in big trials, and it is directly useful to anyone sitting in a clinic deciding what to do next.
For blood sugar, it barely matters
Comparing simultaneous and sequential starts across four studies, the difference in HbA1c at six months was 0.06 of a percentage point, with a p value of 0.55. Fasting glucose showed the same story: a 0.10 difference, not significant.
In other words, however you get there, the glucose benefit is about the same.
That is reassuring. If you are already on one of these drugs and your doctor suggests adding the other, you are not "behind" someone who started both at once. You get to roughly the same place.
For weight, adding the SGLT2 drug second looked better
The overall comparison between simultaneous and sequential starts did not show a significant difference in BMI (1.00, p = 0.09).
But when the authors isolated the group who were already on a GLP-1 drug and then had an SGLT2 inhibitor added, the BMI reduction was significant (1.52, p = 0.02). The paper states it plainly: there was a higher reduction in BMI when an SGLT2 inhibitor was added to GLP-1 therapy rather than the other way round.
Why might that be? One reasonable reading: if your appetite is already turned down by a GLP-1 drug, then the calories you start losing through your urine on an SGLT2 inhibitor are less likely to be eaten back. The appetite brake is already on when the calorie leak starts.
This rests on two studies, so treat it as a pattern worth noticing rather than a rule.
For blood pressure, the opposite order edged ahead
Systolic blood pressure did not differ significantly between simultaneous and sequential routes (2.62, p = 0.10). However, the authors note the reduction was numerically greater in patients who started on an SGLT2 inhibitor and then had a GLP-1 drug added.
That makes sense if you remember that SGLT2 inhibitors are the stronger blood pressure drug of the two, through the sodium and water they flush out. Get that effect established first, then layer the GLP-1 benefits on top.
For kidneys, the order made a visible difference
One of the included studies, Carretero-Gómez and colleagues, looked closely at albumin in the urine. Albumin leaking into urine is one of the earliest signs of kidney damage in diabetes, and a well-established risk factor for both kidney failure and heart disease.
When the drugs were started together, or when a GLP-1 drug was added to an existing SGLT2 inhibitor, the total urine albumin to creatinine ratio fell by a similar amount: 17.19 mg/g and 16.4 mg/g respectively.
But among people with macroalbuminuria, the more advanced leak, the difference between routes was striking:
- SGLT2 inhibitor added to GLP-1: albumin fell by 116.7 mg/g (24 patients)
- GLP-1 added to SGLT2 inhibitor: albumin fell by 55.5 mg/g (21 patients)
More than double the reduction, with a p value under 0.005.
Small groups, one study. But if you have diabetes and your urine test shows protein, that is a detail I would want my doctor to know about.
The Spanish prescription records
The discussion section adds one more data point. A retrospective search of electronic prescriptions for 446,798 people with type 2 diabetes in Spain in 2018 found that starting both drugs together led to faster weight loss and greater HbA1c reduction than starting them one after the other.
So the picture is a little mixed. Starting both at once may speed things up. Adding one to the other gets you to roughly the same glucose control, and depending on which you add second, you may see a better effect on weight or kidneys.
What to take into the appointment
Here is the useful version of all this.
If you are on a GLP-1 drug and still carrying weight or showing protein in your urine, adding an SGLT2 inhibitor looked especially promising in this data.
If you are on an SGLT2 inhibitor and blood pressure is the main concern, adding a GLP-1 drug still helps, and the order you took may already have been the better one for that particular number.
If you are newly diagnosed and your doctor is weighing where to start, the authors lean toward starting both early and together. Their conclusion says that simultaneous use "could prove more beneficial" than sequential. Note the "could". That is a direction, not a settled answer.
None of these are reasons to change anything on your own. They are sharper questions to ask. And sharper questions tend to get better answers.
This series discusses a peer-reviewed meta-analysis of observational studies. Nothing here is medical advice. Do not start, stop or combine prescription medications without your doctor.
